Clinical Trial Update: NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of NEURoaid II (MLC 901) assessing cognitive outcomes in cognitively impaired non-demented subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• NEURoaid II (MLC 901) (MLC 901)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Cognitive Impairment | Phase 2 | Status: COMPLETED